Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IOA-289 in Healthy Volunteers
NCT05027568Phase 1Completed
- Sponsor
- iOnctura
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cambritaxestat in pancreatic cancer (PC) (4 arms), sponsored by iOnctura. Primary endpoint: Numbers of participants with treatment-related adverse events at Day 1. Started Jun 2021; status: completed.
02
Drugs
cambritaxestat
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05027568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027568.